[Unicocell] Application for Clinical Trial Design Change for ELIXCYTE

1. Date of event: 2026/05/29 2. Drug name: ELIXCYTE 3. Purpose: Treatment of knee osteoarthritis 4. Expected stages: Phase 3 clinical trial and new drug registration. 5. Current stage: (1) Received approval for Phase 3 on Feb 8, 2023, and completed enrollment on Nov 12, 2025. Applied for design change to include interim analysis. (2) Risk management: N/A. (3) Future direction: N/A. (4) Accumulated R&D expenses: Not disclosed to protect international licensing negotiations. 6. Next stage: Will be adjusted based on progress. 7. Market status: According to WHO, 528 million people suffer from osteoarthritis globally. The market is expected to reach 15.3 billion USD by 2034. There is a high unmet medical need for long-term effective drug treatments.